Drug Information

Drug General Information
Drug ID
D04HQC
Former ID
DIB001078
Drug Name
SB-9200
Indication HBV infection [ICD9: 070.2-070.3; ICD10:B16, B18.0, B18.1] Phase 1 [524226]
Company
Spring bank pharmaceuticals
Target and Pathway
Target(s) Retinoic acid-inducible gene-1 (RIG-1) Target Info Modulator
Pattern recognition receptor NOD2 Target Info Modulator
KEGG Pathway NF-kappa B signaling pathway
RIG-I-like receptor signaling pathway
Cytosolic DNA-sensing pathway
Hepatitis C
Hepatitis B
Measles
Influenza A
Herpes simplex infection
Epstein-Barr virus infectionhsa04621:NOD-like receptor signaling pathway
TNF signaling pathway
Shigellosis
Tuberculosis
Inflammatory bowel disease (IBD)
Pathway Interaction Database Canonical NF-kappaB pathway
Reactome ISG15 antiviral mechanism
TRAF3-dependent IRF activation pathway
TRAF6 mediated IRF7 activation
TRAF6 mediated NF-kB activation
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
Negative regulators of RIG-I/MDA5 signalingR-HSA-168638:NOD1/2 Signaling Pathway
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
Interleukin-1 signaling
activated TAK1 mediates p38 MAPK activation
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
WikiPathways RIG-I/MDA5 mediated induction of IFN-alpha/beta pathwaysWP2792:MAP kinase activation in TLR cascade
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
Interleukin-1 signaling
NOD pathway
References
Ref 524226ClinicalTrials.gov (NCT01803308) A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naive Adults With Chronic Hepatitis C Infection. U.S. National Institutes of Health.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.